Access Portal Assets
This Stream includes all of our Access Portal Assets Flipbooks
-
View NowPAN EUROPEAN HTA - Where have we been, where are we going?
-
View NowIntegrating Expertise For Product Success
Creating aligned and integrated physician and payer-focused value propositions
-
View Now
What Makes a Good Evidence Generation Plan?
This article will introduce some of the key factors and considerations for a successful evidence generation plan with further articles presenting additional details on specific components of the EGP.
-
View Now
Early Economic Modelling To Inform Decision Making
-
View NowInnovative trial design Health Economics Webinar PPT
-
View Now
Closing the minority gap maximizing ethnic diversity in clinical trials article
This topical article examines the role of the CRO in using culturally specific strategies to engage under-represented patient populations, in order to boost trial recruitment.
-
View NowHTAi Poster_The Furture Model of Oncology Reimbursement
-
View NowHTAi Poster_Future Trends for Managed Access in UK
-
View NowThe Resurrection of the Cost-Minimization Approach in England
-
View NowWould a HST Be Approved in England Under the New Nice Guidance?
-
View NowYour Money or Your Life? Are Price Negotiations HTA Best Practice?
-
View NowThe Impact of pCODR Coming Under the Remit of CADTH - 3 Year Update
-
View Now
Orphan Diseases Translating Expedited Regulatory approval into Reimbursement success article
-
View Now
Innovative Clinical Trial Designs — Welcomed By Regulators But What About The Payers?
-
View NowPatient_Lay_Summaries_Framework_ISMPP_Poster_2017
-
View NowPresentation Slides: Early Engagement Strategies Webinar
-
View NowPromoting the patient voice in evidence generation and global market-access planning
Presentation from the Medical Affairs Leaders Forum, London. February 27 - March 01, 2018
-
View NowSafety Services: A tailored solution to support the needs of large companies
-
View Now
What to look for in a partner to support biosimilar initiatives
This article looks at some of the trends in biosimilars, including three key errors you need to avoid. Particularly, as it pertains to underestimating your risk management plan.
-
View Now
The Importance of QPPVs in Pharmacovigilance
Ian Kovacs, Head of QPPV & Safety Consulting at PAREXEL answers five key questions about the key role of a QPPV and why you should consider outsourcing.
-
Loading More...
